3-Br-PCP
3-Br-PCP is a novel arylcyclohexylamine dissociative research chemical, the 3-bromo analogue of phencyclidine and a halogenated relative of 3-Cl-PCP. It is a potent NMDA antagonist active in low-milligram amounts, with no clinical study and essentially no human toxicology.
01 Overview
3-Br-PCP belongs to the 3-substituted PCP series, which tends to be more potent and longer-acting than PCP itself. Like 3-MeO-PCP and 3-Cl-PCP it is described anecdotally as a potent, stimulating, sometimes anxiogenic dissociative active from a few milligrams.
There are no controlled human studies, no pharmacokinetics and no reliable toxicology. High potency makes accidental overdose easy, and PCP-class dissociatives are associated with agitation, hypertension and, at high doses, delirium. Purity and identity from grey-market suppliers cannot be verified.
02 Mechanism
Potent non-competitive NMDA receptor antagonist of the PCP class; 3-halo substitution increases potency relative to PCP.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Anecdotal (unverified) | 3–12 mg | Oral | Anecdotal only; high potency makes precise volumetric dosing essential. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Stimulating dissociationEnergetic, mind-manifesting dissociation typical of 3-substituted PCP analogues. | unquantified | Anecdotal | |
| AnalgesiaBody numbing reported at higher doses. | unquantified | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Agitation and hypertensionPCP-class dissociatives can cause agitation, tachycardia and raised blood pressure, worse at overdose. | Severe | Unknown, class risk | Anecdotal | |
| Delirium and unknown toxicologyHigh potency and long duration risk overdose delirium; no human safety data exist. | Severe | Unknown | Unconfirmed |